Increased 18F-FDG uptake and expression of Glut1 in the EMT transformed breast cancer cells induced by TGF-β

Neoplasma

Volumn 57, Issue 3, 2010, Pages 234-240

  Li, W ^a   Wei, Z ^a   Liu, Y ^a   Li, H ^a   Ren, R ^b   Tang, Y ^c  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c WEIFANG PEOPLE'S HOSPITAL   (China)

Author keywords

Breast cancer; EMT; Metabolism; TGF

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; TRANSFORMING GROWTH FACTOR BETA; CADHERIN; RADIOPHARMACEUTICAL AGENT; SLC2A1 PROTEIN, HUMAN; VIMENTIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL METABOLISM; CELL TRANSFORMATION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; EPITHELIUM CELL; IMMUNOFLUORESCENCE; MESENCHYME CELL; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; WESTERN BLOTTING; BREAST TUMOR; CELL MOTION; CHEMISTRY; FEMALE; HUMAN; MESODERM; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MESODERM; RADIOPHARMACEUTICALS; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

EID: 77954651220     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_03_234     Document Type: Article

References (45)

1. LARUE L, BELLACOSA A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24: 7443-7454. doi:10.1038/sj.onc.1209091
2. SPADERNA S, SCHMALHOFER O, HLUBEK F, Epithelialmesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol. 2007; 91: 21-28.
3. SAVAGNER P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001; 23(10): 912-923. doi:10.1002/bies.1132
4. LEE JM, DEDHAR S, KALLURI R, THOMSON EW et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172: 973-981. doi:10.1083/jcb.200601018
5. HIROHASHI S, KANAI Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci. 2003; 94: 575-581. doi:10.1111/j.1349-7006.2003.tb01485.x
6. THIERY JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003; 15: 740-746. doi:10.1016/j.ceb.2003.10.006
7. HUBER MA, KRAUT N, BEUG H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17(5): 548-558. doi:10.1016/j.ceb.2005.08.001
8. FREDERICK BA, HELFRICH BA, COLDREN CD, ZHENG D, CHAN D, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007; 6: 1683-1691. doi:10.1158/1535-7163.MCT-07-0138
9. LAVAYSSIÈRE R, CABÉE AE, FILMONT JE. Positron Emission Tomography (PET) and breast cancer in clinical practice. Eur J Radiol. 2009; 69: 50-58. doi:10.1016/j.ejrad.2008.07.039
10. EUBANK WB, MANKOFF DA. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med 2004; 34: 224-240. doi:10.1053/ j.semnuclmed.2004.03.007
11. FARSAD M, SCHIAVINA R, FRANCESCHELLI A, SANGUEDOLCE F, CASTELLUCCI P, et al. Positron-emission tomography in imaging and staging prostate cancer. Cancer Biomark. 2008; 4: 277-284.
12. MITTRA E, QUON A. Positron emission tomography/computed tomography: the current technology and applications. Radiol Clin North Am. 2009; 47(1): 147-160. doi:10.1016/ j.rcl.2008.10.005
13. LESTER RD, JO M, MONTEL V, TAKIMOTO S, GONIAS SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 2007; 178: 425-36. doi:10.1083/ jcb.200701092
14. SMITH TA, SHARMA RI, THOMPSON AM, PAULIN FE. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. The journal of nuclear medicine. 2006; 47: 1525-1530.
15. ENGLES JM, QUARLESS SA, MAMBO E, ISHIMORI T, CHO SY, et al. Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med. 2006; 47: 603-608.
16. MOUSTAKAS A, HELDIN CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007; 98: 1512-1520. doi:10.1111/j.1349-7006.2007.00550.x
17. GUPTA GP, MASSAGUÉ J. Cancer metastasis: building a framework. Cell. 2006; 127: 679-695. doi:10.1016/j.cell.2006.11.001
18. KALLURI R, WEINBERG RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-1428. doi:10.1172/JCI39104
19. SARRIÓ D, RODRIGUEZ-PINILLA SM, HARDISSON D, CANO A, MORENO-BUENO G, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008; 68: 989-997. doi:10.1158/0008-5472.CAN-07-2017
20. MANI SA, GUO W, LIAO MJ, EATON EN, AYYANAN A, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-715. doi:10.1016/ j.cell.2008.03.027
21. MOODY SE, PEREZ D, PAN TC, SARKISIAN CJ, PORTOCARRERO CP, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005; 8: 197-209. doi:10.1016/j.ccr.2005.07.009
22. FUCHS IB, LICHTENEGGER W, BUEHLER H, HENRICH W, STEIN H, et al. The prognostic significance of epithelialmesenchymal transition in breast cancer. Anticancer Res. 2002; 22: 3415-3419.
23. KOKKINOS MI, WAFAI R, WONG MK, NEWGREEN DF, THOMPSON EW, et al. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs. 2007; 185: 191-203. doi:10.1159/000101320
24. LI QQ, XU JD, WANG WJ, CAO XX, CHEN Q, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009; 15: 2657-2665. doi:10.1158/1078-0432.CCR-08-2372
25. MAEDA M, JOHNSON KR, WHEELOCK MJ. Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci. 2005; 118: 873-887. doi:10.1242/jcs.01634
26. LEHEMBRE F, YILMAZ M, WICKI A, SCHOMBER T, STRITTMATTER K, et al. NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J. 2008; 27: 2603-2615. doi:10.1038/emboj.2008.178
27. GRAVDAL K, HALVORSEN OJ, HAUKAAS SA, AKSLEN LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007; 13: 7003-7011. doi:10.1158/1078-0432. CCR-07-1263
28. THIERY JP, SLEEMAN JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7: 131-142. doi:10.1038/nrm1835
29. KORPAL M, LEE ES, HU G, KANG Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283: 14910-14914. doi:10.1074/jbc.C800074200
30. KABASHIMA A, HIGUCHI H, TAKAISHI H, MATSUZAKI Y, SUZUKI S, et al. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer. 2009; 124: 2771-2779. doi:10.1002/ijc.24349
31. PEINADO H, PORTILLO F, CANO A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004; 48: 365-375. doi:10.1387/ijdb.041794hp
32. BUIJS JT, HENRIQUEZ NV, VAN OVERVELD PG, VAN DER HORST G, TEN DIJKE P, et al. TGF-beta and BMP7 interactions in tumour progression and bone metastasis. Clin Exp Metastasis. 2007; 24: 609-617. doi:10.1007/s10585-007-9118-2
33. GUO A, VILLÉN J, KORNHAUSER J, LEE KA, STOKES MP, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008; 105: 692-697. doi:10.1073/pnas.0707270105
34. GRANDIS JR, SOK JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004; 102 (1): 37-46. doi:10.1016/j.pharmthera.2004.01.002
35. BUCK E, EYZAGUIRRE A, BARR S, THOMPSON S, SENNELLO R, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 2007; 6: 532-541. doi:10.1158/1535-7163.MCT-06-0462
36. HADDAD Y, CHOI W, MCCONKEY DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 2009; 15: 532-542. doi:10.1158/1078-0432.CCR-08-1733
37. SHRADER M, PINO MS, BROWN G, BLACK P, ADAM L, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007; 6: 277-285. doi:10.1158/1535-7163.MCT-06-0513
38. BARR S, THOMSON S, BUCK E, RUSSO S, PETTI F, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis. 2008; 25: 685-693. doi:10.1007/s10585-007-9121-7
39. ZHANG B, GROFFEN J, HEISTERKAMP N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia. 2007; 21: 1189-1197. doi:10.1038/sj.leu.2404667
40. RODRÍGUEZ-PINILLA SM, SARRIÓ D, HONRADO E, HARDISSON D, CALERO F, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12: 1533-539. doi:10.1158/1078-0432.CCR-05-2281
41. AZIZUN-NISA, BHURGRI Y, RAZA F, KAYANI N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008; 9: 553-556.
42. BROUCKAERT O, PINTENS S, VAN BELLE V, VAN HUFFEL S, CAMERLYNCK E, et al. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors. Breast Cancer Res Treat. 2009; 115: 349-258. doi:10.1007/ s10549-008-0110-6
43. ROHREN EM, TURKINGTON TG, COLEMAN RE. Clinical applications of PET in oncology. Radiology 2004, 231 (2): 305-332. doi:10.1148/radiol.2312021185
44. LINDHOLM P, LAPELA M, NÅGREN K, LEHIKOINEN P, MINN H, et al. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun. 2009; 30: 30-36.
45. ALMUBARAK M, OSMAN S, MARANO G, ABRAHAM J. Role of positron-emission tomography scan in the diagnosis and management of breast cancer. Oncology (Williston Park). 2009; 23: 255-261.